Small molecule drugs with immunomodulatory effects in cancer

References

• Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694
   PubMed Web of Science ®Google Scholar
• Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, et al. Safety and survival with GVAX pancreas prime and listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol 2015; 33:1325-33; PMID:25584002; http://dx.doi.org/10.1200/JCO.2014.57.4244
   PubMed Web of Science ®Google Scholar
• Hoelder S, Clarke PA, Workman P. Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol 2012; 6:155-76; PMID:22440008; http://dx.doi.org/10.1016/j.molonc.2012.02.004
   PubMed Web of Science ®Google Scholar
• Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010; 28:4485-91; PMID:20697094; http://dx.doi.org/10.1200/JCO.2010.28.9066
   PubMed Web of Science ®Google Scholar
• West AC, Mattarollo SR, Shortt J, Cluse LA, Christiansen AJ, Smyth MJ, Johnstone RW. An intact immune system is required for the anticancer activities of histone deacetylase inhibitors. Cancer Res 2013; 73:7265-76; PMID:24158093; http://dx.doi.org/10.1158/0008-5472.CAN-13-0890
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10:223-32; PMID:19230772; http://dx.doi.org/10.1016/S1470-2045(09)70003-8
   PubMed Web of Science ®Google Scholar
• Daurkin I, Eruslanov E, Vieweg J, Kusmartsev S. Generation of antigen-presenting cells from tumor-infiltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2'-deoxycytidine. Cancer Immunol Immunotherapy 2010; 59:697-706; PMID:19882154; http://dx.doi.org/10.1007/s00262-009-0786-4
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR, Eastern cooperative oncology G. phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the eastern cooperative oncology group. J Clin Oncol 2006; 24:431-6; PMID:16365178; http://dx.doi.org/10.1200/JCO.2005.03.0221
   PubMed Web of Science ®Google Scholar
• Eigentler TK, Kamin A, Weide BM, Breuninger H, Caroli UM, Mohrle M, Radny P, Garbe C. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. J Am Acad Dermatol 2007; 57:616-21; PMID:17610993; http://dx.doi.org/10.1016/j.jaad.2007.05.022
   PubMed Web of Science ®Google Scholar
• Schon MP, Schon M. Imiquimod: mode of action. British J Dermatol 2007; 157 2:8-13; http://dx.doi.org/10.1111/j.1365-2133.2007.08265.x
   PubMed Web of Science ®Google Scholar
• Huh JR, Littman DR. Small molecule inhibitors of RORgammat: targeting Th17 cells and other applications. Europ J Immunol 2012; 42:2232-7; PMID:22949321; http://dx.doi.org/10.1002/eji.201242740
   PubMed Web of Science ®Google Scholar
• Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 9:1269-74; PMID:14502282; http://dx.doi.org/10.1038/nm934
   PubMed Web of Science ®Google Scholar
• Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005; 11:312-9; PMID:15711557; http://dx.doi.org/10.1038/nm1196
   PubMed Web of Science ®Google Scholar
• Prendergast GC. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 2008; 27:3889-900; PMID:18317452; http://dx.doi.org/10.1038/onc.2008.35
   PubMed Web of Science ®Google Scholar
• Smith C, Chang MY, Parker KH, Beury DW, DuHadaway JB, Flick HE, Boulden J, Sutanto-Ward E, Soler AP, Laury-Kleintop LD, et al. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov 2012; 2:722-35; PMID:22822050; http://dx.doi.org/10.1158/2159-8290.CD-12-0014
   PubMed Web of Science ®Google Scholar
• Witkiewicz A, Williams TK, Cozzitorto J, Durkan B, Showalter SL, Yeo CJ, Brody JR. Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. J Am College Surgeons 2008; 206:849-54; discussion 54-6; PMID:18471709; http://dx.doi.org/10.1016/j.jamcollsurg.2007.12.014
   PubMed Web of Science ®Google Scholar
• Ferdinande L, Decaestecker C, Verset L, Mathieu A, Moles Lopez X, Negulescu AM, Van Maerken T, Salmon I, Cuvelier CA, Demetter P. Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer. British J Cancer 2012; 106:141-7; PMID:22108515; http://dx.doi.org/10.1038/bjc.2011.513
   PubMed Web of Science ®Google Scholar
• Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A, Fioretti MC, Puccetti P. T cell apoptosis by tryptophan catabolism. Cell Death Differentiation 2002; 9:1069-77; PMID:12232795; http://dx.doi.org/10.1038/sj.cdd.4401073
   PubMed Web of Science ®Google Scholar
• Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, Messina JL, Chandler P, Koni PA, Mellor AL. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004; 114:280-90; PMID:15254595; http://dx.doi.org/10.1172/JCI200421583
   PubMed Web of Science ®Google Scholar
• Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, Azuma M, Blazar BR, Mellor AL, Munn DH. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clinical Investigation 2007; 117:2570-82; PMID:17710230; http://dx.doi.org/10.1172/JCI31911
   PubMed Web of Science ®Google Scholar
• Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, Mellor AL, Prendergast GC, Munn DH. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007; 67:792-801; PMID:17234791; http://dx.doi.org/10.1158/0008-5472.CAN-06-2925
   PubMed Web of Science ®Google Scholar
• Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011; 478:197-203; PMID:21976023; http://dx.doi.org/10.1038/nature10491
   PubMed Web of Science ®Google Scholar
• Soliman HH, Jackson E, Neuger T, Dees EC, Harvey RD, Han H, Ismail-Khan R, Minton S, Vahanian NN, Link C, et al. A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget 2014; 5:8136-46; PMID:25327557
   PubMedGoogle Scholar
• Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K, Leffet L, Hansbury MJ, Thomas B, Rupar M, et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 2010; 115:3520-30; PMID:20197554; http://dx.doi.org/10.1182/blood-2009-09-246124
   PubMed Web of Science ®Google Scholar
• Beatty GL, O'Dwyer PJ, Clark J, Shi JG, Newton RC, Schaub R, Maleski J, Leopold L, Gajewski T. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies. J Clin Oncol 2013; 31 (suppl; abstr 3025).
   Google Scholar
• Newton RC, Scherle PA, Bowman K, Liu X, Beatty GL, O'Dwyer PJ, Gajewski T, Bowman J, Schaub R, Leopold L. Pharmacodynamic assessment of INCB024360, an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), in advanced cancer patients. J Clin Oncol 30, 2012 (suppl; abstr 2500^)
   Google Scholar
• Hiscox AG H, Couto J, Liao Z, Zhu Y, Liu X, Newton RC, Hnatyszyn J. Development of an IHC-based detection method for studying indoleamine 2,3-dioxygenase 1 (IDO1) expression in human cancers. 2014 ASCO annual meeting. J Clin Oncol 2014:5s 3043
   Google Scholar
• Gibney GTHO, Gangadhar TC, Lutzky J, Olszanski AJ, Gajewski T, Chmielowski B, Boasberg PD, Zhao Y, Newton RC, Scherle PA, et al. Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. J Clin Oncol 2014; 32:3010
   Google Scholar
• Khleif SMD, Nyak-Kapoor A, Mautino MR, Kennedy E, Vahanian NN, Link CJ. First-in-human phase 1 study of the novel indoleamine-2,3-dioxygenase (IDO) inhibitor NLG-919. J Clin Oncol 2014; 32:5s:TPS3121
   Google Scholar
• Iversen TZ, Engell-Noerregaard L, Ellebaek E, Andersen R, Larsen SK, Bjoern J, Zeyher C, Gouttefangeas C, Thomsen BM, Holm B, et al. Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clin Cancer Res 2014; 20:221; PMID:24218513; http://dx.doi.org/10.1158/1078-0432.CCR-13-1560
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr. ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res 2012; 66:105-43; PMID:22569528; http://dx.doi.org/10.1016/j.phrs.2012.04.005
   PubMed Web of Science ®Google Scholar
• Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res 2012; 72:2457-67; PMID:22589270; http://dx.doi.org/10.1158/0008-5472.CAN-11-2612
   PubMed Web of Science ®Google Scholar
• Engel MA, Neurath MF. Anticancer properties of the IL-12 family–focus on colorectal cancer. Current Med Chem 2010; 17:3303-8; PMID:20712574; http://dx.doi.org/10.2174/092986710793176366
   PubMed Web of Science ®Google Scholar
• Puig-Kroger A, Relloso M, Fernandez-Capetillo O, Zubiaga A, Silva A, Bernabeu C, Corbi AL. Extracellular signal-regulated protein kinase signaling pathway negatively regulates the phenotypic and functional maturation of monocyte-derived human dendritic cells. Blood 2001; 98:2175-82; PMID:11568005; http://dx.doi.org/10.1182/blood.V98.7.2175
   PubMed Web of Science ®Google Scholar
• Arrighi JF, Rebsamen M, Rousset F, Kindler V, Hauser C. A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-α, and contact sensitizers. J Immunol 2001; 166:3837-45; PMID:11238627; http://dx.doi.org/10.4049/jimmunol.166.6.3837
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. New Engl J Med 2012; 367:107-14; PMID:22663011; http://dx.doi.org/10.1056/NEJMoa1203421
   PubMed Web of Science ®Google Scholar
• Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. New Engl J Med 2015; 372:30-9; PMID:25399551; http://dx.doi.org/10.1056/NEJMoa1412690
   PubMed Web of Science ®Google Scholar
• Bendell JCACE, André T, Tabernero J, Gordon MS, Bernards R, Van Cutsem E, Tejpar S, Sidhu R, Go WY, Allred A, et al. Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC). J Clin Oncol 32:5s 2014 3515
   Google Scholar
• Hochster HS, Uboha N, Messersmith W, Gold PJ, BH ON, Cohen D, Denlinger C, Cohen S, Leichman CG, Leichman L, et al. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Cancer Chemotherapy Pharmacol 2015; 75:17-23; http://dx.doi.org/10.1007/s00280-014-2609-3
   PubMed Web of Science ®Google Scholar
• Do K, Speranza G, Bishop R, Khin S, Rubinstein L, Kinders RJ, Datiles M, Eugeni M, Lam MH, Doyle LA, et al. Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer. Investigational New Drugs 2015; 33(3): 720–8; PMID:25637165
   PubMed Web of Science ®Google Scholar
• Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol 2011; 29:2357-63; PMID:21519026; http://dx.doi.org/10.1200/JCO.2010.33.9473
   PubMed Web of Science ®Google Scholar
• Finn RSJMM, Tan, BR, Weekes CD, Bendell JC; Patnaik A, Khan GN, Laheru D, Anderson L, Christy-Bittel JL, Barrett E et al. A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer. 2010 ASCO GI conference. J Clin Oncol 2012:4 220
   Google Scholar
• Van Cutsem EH, Bazin MI, Canon JL, Poddubskaya E, Manojlovic N, Milella M, Radenkovic D, Verslype C, Guo W, Damstrup L, et al. Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer. J Clin Oncol 2015; 33:3 344
   Google Scholar
• Van Laethem JL, Jassem J, Heinemann V, Weekes CD, Bridgewater JA, Cascinu S, Melichar B, Peeters M, Ross PJ, Saramak P, Giurescu M, et al. Phase II study of refametinib (BAY 86-9766), an allosteric dual MEK 1/2 inhibitor, and gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer. J Clin Oncol 2014; 32 (suppl; abstr 4025).
   Google Scholar
• Wang D, Boerner SA, Winkler JD, LoRusso PM. Clinical experience of MEK inhibitors in cancer therapy. Biochimica et Biophysica Acta 2007; 1773:1248-55; PMID:17194493; http://dx.doi.org/10.1016/j.bbamcr.2006.11.009
   PubMed Web of Science ®Google Scholar
• Renouf DJ, Velazquez-Martin JP, Simpson R, Siu LL, Bedard PL. Ocular toxicity of targeted therapies. J Clin Oncol 2012; 30:3277-86; PMID:22649132; http://dx.doi.org/10.1200/JCO.2011.41.5851
   PubMed Web of Science ®Google Scholar
• Chen X, Schwartz GK, DeAngelis LM, Kaley T, Carvajal RD. Dropped head syndrome: report of three cases during treatment with a MEK inhibitor. Neurology 2012; 79:1929-31; PMID:23077008; http://dx.doi.org/10.1212/WNL.0b013e318271f87e
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013; 14:249-56; PMID:23414587; http://dx.doi.org/10.1016/S1470-2045(13)70024-X
   PubMed Web of Science ®Google Scholar
• Chen MH, Kerkela R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 2008; 118:84-95; PMID:18591451; http://dx.doi.org/10.1161/CIRCULATIONAHA.108.776831
   PubMed Web of Science ®Google Scholar